548 related articles for article (PubMed ID: 19105036)
1. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
3. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells.
Kobayashi-Sakamoto M; Isogai E; Holen I
Eur J Haematol; 2010 Jul; 85(1):26-35. PubMed ID: 20331738
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced mitogenic factor enhances angiogenesis by promoting proliferation and migration of endothelial cells.
Tong Q; Zheng L; Li B; Wang D; Huang C; Matuschak GM; Li D
Exp Cell Res; 2006 Nov; 312(18):3559-69. PubMed ID: 16982054
[TBL] [Abstract][Full Text] [Related]
6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
7. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
8. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis.
Hung SC; Pochampally RR; Chen SC; Hsu SC; Prockop DJ
Stem Cells; 2007 Sep; 25(9):2363-70. PubMed ID: 17540857
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
11. Biology of RANK, RANKL, and osteoprotegerin.
Boyce BF; Xing L
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
[TBL] [Abstract][Full Text] [Related]
12. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis.
Lovren F; Pan Y; Shukla PC; Quan A; Teoh H; Szmitko PE; Peterson MD; Gupta M; Al-Omran M; Verma S
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1440-9. PubMed ID: 19351806
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.
Dai J; Peng L; Fan K; Wang H; Wei R; Ji G; Cai J; Lu B; Li B; Zhang D; Kang Y; Tan M; Qian W; Guo Y
Oncogene; 2009 Sep; 28(38):3412-22. PubMed ID: 19597469
[TBL] [Abstract][Full Text] [Related]
15. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation.
Kobayashi-Sakamoto M; Isogai E; Hirose K; Chiba I
Microvasc Res; 2008 Nov; 76(3):139-44. PubMed ID: 18656492
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo.
Mannell H; Hellwig N; Gloe T; Plank C; Sohn HY; Groesser L; Walzog B; Pohl U; Krotz F
J Vasc Res; 2008; 45(2):153-63. PubMed ID: 17962719
[TBL] [Abstract][Full Text] [Related]
17. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
Wang BL; Zheng F; Qiu MC
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
20. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.
Corallini F; Celeghini C; Rimondi E; di Iasio MG; Gonelli A; Secchiero P; Zauli G
J Cell Physiol; 2011 Sep; 226(9):2279-86. PubMed ID: 21660951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
